High-risk speculative growth investors and biotech-focused funds willing to accept binary outcomes.
High sensitivity through multiple channels: (1) Higher rates compress valuation multiples for pre-revenue growth stocks…
Watch on earnings: Monthly cash burn rate and quarters of cash runway remaining, Quarterly test volumes and revenue per test trends, Number of contracted provider sites and geographic expansion.
One Sentence Summary:
Firefly Neuroscience: the story is balanced — fda regulatory milestones or expanded clearances for new indications beyond adhd.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.